Since its founding in 1994, Pappas Capital has guided the launch and/or development of more than 70 life science companies, with a commitment to bringing promising products and technologies to market.
Scott Weiner and Kyle Rasbach, Partners at Pappas Capital, will be visiting JLABS @ South San Francisco on June 5, 2018 to provide an overview of Pappas Capital’s investment strategy and meet one-on-one with pre-selected companies.
Pappas Capital invests exclusively in the life sciences sector - biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures - across the United States and Canada. The firm has raised more than $500 million across multiple funds, and has built a team with extensive experience in sourcing, evaluating, building and exiting life science companies. More than one-third of their 70 portfolio companies have successfully been acquired or completed initial public offerings.